BioSpace News Archive

Achieve Life Sciences, Inc. today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024.

Nautilus Biotechnology, Inc. today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston.

Tevogen Bio Holdings, is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.

Prime Therapeutics LLC / Magellan Rx Management, LLC continues to publish award-winning and industry-leading research on a range of clinical topics impacting the health care and pharmacy benefit management industry. Thought leaders from Prime/MRx will present eight research studies at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting, April 15-18 in New Orleans.

Johnson & Johnson today announced the planned presentation of new non-clinical studies underscoring the molecular properties of nipocalimab, an investigational fully human monoclonal antibody targeting the neonatal fragment crystallizable receptor (FcRn).

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.

Sania Therapeutics, focused on developing targeted genetic medicines for prevalent disorders announces that it will be presenting three posters at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place from 7-11 May 2024 in Baltimore, MD. Further details are below.

Arvinas, Inc. announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor degrader for patients with prostate cancer.